Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFOLFIRINOX + anlotinib + sintilimab
- Development stage
- Unknown
- Lead developer
- Fujian Provincial Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
mFOLFIRINOX + anlotinib + sintilimab is a combination therapy regimen being evaluated for the first-line treatment of locally advanced or metastatic pancreatic cancer. The regimen combines the cytotoxic chemotherapy backbone mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, and oxaliplatin) with anlotinib, a multi-targeted tyrosine kinase inhibitor, and sintilimab, an anti-PD-1 monoclonal antibody. Anlotinib suppresses tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, and c-Kit. Sintilimab acts as an immune checkpoint inhibitor, blocking the interaction between PD-1 and its ligands to restore T-cell mediated anti-tumor activity. This multi-modal approach, sponsored by Fujian Provincial Hospital, aims to enhance therapeutic efficacy by simultaneously targeting DNA replication, angiogenesis, and immune evasion in pancreatic ductal adenocarcinoma.
- Other names
- mFOLFIRINOX combined with anlotinib and sintilimab
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on mFOLFIRINOX + anlotinib + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFOLFIRINOX + anlotinib + sintilimab.